Study Suggests Survival Advantage for Ovarian Cancer Patients with BRCA Mutations | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The five-year survival rate for individuals with invasive epithelial ovarian cancer is generally higher for women with mutations in BRCA1 or BRCA2 than it is for those without, according to a new study in the Journal of the American Medical Association.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Dec
08
Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.